D1.107 - Polyphenol concentrate reduces CRP in asthma patients who have had COVID-19

A number of studies have been conducted on the effect of pharmacological drugs on low-grade inflammation (LGI), however, despite the effectiveness of some drugs in relation to LGI, they have a number of limitations due to the presence of undesirable effects with prolonged use. New drugs and means of suppressing LGI are being sought including grape polyphenols.

The study included 70 patients with a verified diagnosis of asthma who had COVID-19. The patients were divided into two groups. Group 1 (n=40), in addition to standard treatment, received a concentrate of grapes polyphenols, according to the manufacturer's instructions in a dosage of 1 teaspoon per day during meals. Group 2 consisted of 30 patients who were comparable in gender and age to the experimental group. All patients had the  content of CRP (Me (Q1-Q3); mg/L) in plasma determined by quantitative high-sensitivity enzyme-linked immunosorbent assay using ELISA test manufactured by Cloud Clone corp. (Wuhan, Hubei, China).

In patients of Group 1, after a course of polyphenol concentrate, a significant decrease in the level of CRP from 2.88 (0.54-3.53) to 2.19 (0.87-3.16) (p=0.039) was seen. There were no significant changes in the level of CRP in Group 2 (p=0.198).

The use of polyphenolic grape concentrates in patients in the post-covid period reduces the level of CRP, which should reduce the likelihood of long-term effects associated with LGI, including cardiovascular, in patients who have had COVID-19.